Over the weekend you may have seen headlines announcing that a “‘Universal’ cancer vaccine” or “wonder jab” has been developed by Israeli researchers.
In fact, the story behind the headlines is about unpublished interim clinical trial results from just seven patients given ImMucin, a new vaccine targeting a protein called MUC1 which is found on the surface of many cancer cells.
We are concerned that some of the coverage of this story has been over-hyped and misleading – something that is particularly pertinent given the focus on responsible science and health reporting as part of the ongoing Leveson Inquiry (pdf).
The science behind the headlines
MUC1, or mucin 1, is a sticky, sugary protein found on the surface of healthy cells, including the lining of the gut, lungs and stomach. It helps to protect the body from infection in the same way that flypaper protects a kitchen, by forming a sticky surface that traps bacteria and prevents them from infecting cells.
As well as playing an important role in healthy tissue, high levels of MUC1 are found in many different types of cancer, including breast, pancreatic and lung cancer. It’s thought that it helps cancer cells to spread through the body, and resist the cell-killing effects of chemotherapy
Cancer researchers around the world have known about MUC1 for a long time. Indeed, some of our leading scientists, Professor Joyce Taylor-Papadimitriou and Dr Joy Burchell, pioneered research into MUC1 throughout the 1980s and 90s, revealing how it is involved in cancer and how it might be targeted by the immune system.
Because it’s found in so many different cancers, MUC1 is understandably a very attractive target for the development of cancer treatments. This includes ‘cancer vaccines’ like ImMucin, which train a patient’s immune system to recognise tumour cells carrying MUC1 and destroy them.
But ImMucin is certainly not the first MUC1 vaccine to be developed, and it’s a long way behind some of the leaders in the field. For example, Stimuvax – a MUC1 vaccine that we helped to develop – is currently in large scale clinical trials involving hundreds of patients with various types of cancer, and there are others in the pipeline too.
It’s important to be cautious about the results from the early-stage trial of ImMucin reported in the media, which are based on data from seven patients (out of ten treated so far) with multiple myeloma – a cancer affecting the immune system.
Furthermore, the team’s results are yet to be published in the scientific literature – the ‘gold standard’ for reliable research. Instead, the results have come directly from a press release from Vaxil Biotherapeutics Ltd, the company that makes the vaccine – something that wasn’t made clear in some of the media coverage of the story.
According to the company’s report, three patients out of seven have had a “complete response” – meaning that their cancer can no longer be detected, although this doesn’t necessarily mean a long-term cure. It’s also not clear how long this remission has lasted, or how any of these patients are doing now.
While MUC1 is certainly an important target in cancer and the results from the handful of myeloma patients in the ImMucin trial look promising, it’s a far cry from being a “wonder jab” that “kills 90% of all cancers”.
As we point out in our comment which we gave to the Daily Telegraph, “There are several groups around the world investigating treatments that target MUC1, as it’s a very interesting target involved in several types of cancer. These are very early results that are yet to be fully published, so there’s a lot more work to be done to prove that this particular vaccine is safe and effective in cancer patients.”
We’ve already been contacted by cancer patients wondering how to get access to this “wonder jab” as a result of the news coverage. As we’ve said before, over-hyped stories like this only serve to raise false hopes in people suffering from cancer and mislead the public.
Every day cancer researchers in labs and hospitals around the world are making huge strides against this terrible disease, and their progress and successes deserve to be reported to the public. But misrepresenting and over-selling their early baby-steps isn’t helpful to anyone, most of all cancer patients and their families.
Telemedicine Saves Australian Hospital $705000 in Travel Costs Business 2 Community More than half of the world's population lives in or near a major city, where getting medical care quickly and easily is nearly taken for granted.
MediSafe is a cloud-based app system — the patients get a reminder to take their meds on their Android or Apple smartphone app, and are then prompted to record it if they do. If they don’t indicate that they’ve taken their dose, a graduated series of friends and family is informed and can take action.
“It pushes you a notification when its time to take your meds,” MediSafe CEO Omri “Bob” Shor told MobiHealthNews in January. “The first one is a quiet one, like a text message. The second one is a louder one. The third one you can’t ignore, and the fourth one goes to your wife.”
The company will use the money to build up strategic partnerships with pharma companies, pharmacies, HMOs, employers and hospitals. MediSafe hopes to be valuable to those stakeholders because it not only can increase patients’ medication adherence, but it also collects de-identified aggregate data about patients’ adherence.
With one half of health industry executives saying they are concerned about how to integrate social media data into their business strategy there is a recognition social media presents a significant industry challenge.
EnteroMedics Inc., (NASDAQ: ETRM) is a St. Paul, MN based medical device company established in 2002 to develop and commercialize a therapeutic neuroblocking platform for treating a range of acute and chronic gastrointestinal and metabolic diseases mediated by the vagus nerve.
U.S. Food and Drug Administration (FDA) Issues Final Mobile Medical App ... The National Law Review Enable patients or providers to interact with Personal Health Records (PHR) or Electronic Health Record (EHR) systems.
With the proliferation of smartphones and tablets, mobile technologies are quickly being adopted as a means to alleviate certain physician pain points and strengthen patient self-management. The recently released Meaningful Use Stage 2 objectives hold a larger focus on patient engagement, and mobile health holds promise as a key tool in helping organizations address these requirements. In fact, many of the engagement objectives that were optional in Stage 1 – such as patient reminders and education resources – are now required in Stage 2. Additionally, many of the Stage 2 rules reference the delivery of results directly to patients.
The Information Daily £1 billion to be invested in new digital technology for the NHS The Information Daily The government says it is committed to ensuring that patients will be able to book GP appointments and order repeat prescriptions online, as...
Health care is increasingly featured by the use of Web 2.0 communication and collaborative technologies that are reshaping the way patients and professionals interact. [In the Netherlands] One in 4 persons wants to communicate with their physician via social media channels and it is expected that this number will further increase. Health care providers should explore new ways of communicating online and should facilitate ways for patients to connect with them.
MedCity News Which of these 8 ideas to transform healthcare will Robert Wood Johnson ... MedCity News Mapping human exposome You've probably heard about the project to successfully map the human genome but what about the human exposome?
Sharing your scoops to your social media accounts is a must to distribute your curated content. Not only will it drive traffic and leads through your content, but it will help show your expertise with your followers.
How to integrate my topics' content to my website?
Integrating your curated content to your website or blog will allow you to increase your website visitors’ engagement, boost SEO and acquire new visitors. By redirecting your social media traffic to your website, Scoop.it will also help you generate more qualified traffic and leads from your curation work.
Distributing your curated content through a newsletter is a great way to nurture and engage your email subscribers will developing your traffic and visibility.
Creating engaging newsletters with your curated content is really easy.